The combination use of niraparib (Zejula) plus bevacizumab (Avastin) significantly improved clinical outcomes, compared with niraparib alone, in patients with recurrent ovarian cancer, according to updated survival data from the phase 2 portion of the AVANOVA trial (NSGO-AVANOVA2/ENGOT-OV24; NCT02354131) that were made available as part of the 2020 ASCO Virtual Scientific Program.1
The updated results continued to support earlier findings, with an observed 66% reduction in the risk of disease progression or death (HR, 0.34; 95% CI, 0.21-0.54). The median progression-free survival (PFS) in the bevacizumab arm was 12.5 months versus 5.5 months with niraparib alone.
Statistically significant improvements in time to second progression or death, or PFS2, was demonstrated in the bevacizumab/niraparib combination arm versus the niraparib control, with corresponding medians of 20.5 versus 15.7…
